RxDoctor Payments Data

Jennifer Bass, OD

Optometrist · Mt Vernon, ILNPI 1922009950

Payments from drug & device makers

$3,064in general payments, 2019–2025

Across 151 payments — averaging $20.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$840
  • Bausch & Lomb Americas Inc.$571
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$296
  • Alcon$193
  • AbbVie$190
  • Tarsus Pharmaceuticals, Inc.$172
  • plus $803 from 9 others

What the payments were for

  • Speaking & faculty fees$120%
  • Food & beverage$3,03599%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,064 in reported general payments places this provider in the 90th percentile of 2,257 optometrist providers in Illinois.

See all optometrist providers in Illinois

Medicare billing

Part B allowed, 2024
$76,942
Medicare patients
598
Services billed
8,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine36$27,314
LumiganBimatoprost35$18,330
Cyclosporine26$12,461
MieboPerfluorohexyloctane/Pf11$8,358
Travoprost14$2,873
Epinastine Hcl38$2,357
Latanoprost42$545
Brimonidine Tartrate15$505
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat21$424
Dorzolamide Hcl19$364
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha23$244
Timolol Maleate19$185

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$190$45,64471 claims
Bausch & Lomb Americas Inc.Miebo$571$8,35811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,257 optometrist providers in Illinois.

Other optometrist in Mt Vernon

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →